Anderson Karen S, Gerber Jennifer E, D'Souza Gypsyamber, Pai Sara I, Cheng Julia N, Alam Rizwan, Kesiraju Sailaja, Chowell Diego, Gross Neil D, Haddad Robert, Gillison Maura L, Posner Marshall
Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ 85287, United States.
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States.
Oral Oncol. 2015 Aug;51(8):751-8. doi: 10.1016/j.oraloncology.2015.05.007. Epub 2015 Jun 18.
We hypothesized that viral and host factors impact the serologic responses to HPV early antigens in HPV-positive oropharyngeal cancer (HPVOPC).
We conducted a multicenter study to measure HPV16-specific IgG among patients with HPVOPC, their long-term sexual partners, and healthy volunteers. Risk factor surveys and rinse and gargle specimens were collected. Peripheral blood samples at diagnosis were evaluated for IgG Abs to HPV16 antigens using a programmable ELISA assay. Predictors for HPV16 serologic responses were evaluated using univariate and multivariable linear regression.
116 patients with HPVOPC, 43 partners, and 81 healthy volunteers were enrolled and had baseline sera for analysis. Cases were primarily male (90%), with a median age of 56 years. Abs to E1, E2, E6 or E7 antigens were detected more often in HPVOPC compared with volunteers or partner sera (p<0.0001). HPV16 Abs to at least one early protein (E1, E2, E4, E5, E6, or E7) were detected in the sera of 90.6% of cases, 0% of partners and 7.4% of healthy volunteers. Gender, race, sexual behavior, and viral integration were not associated with antibody response. Younger age and higher oral HPV16 copy number were associated with higher HPV16 E6 and NE2 antibody levels.
HPV16 seroreactivity is commonly detected among patients with HPVOPC at diagnosis, but not among partners or healthy volunteers. Seroreactivity among cases are correlated with viral load and stage and not with other demographic or behavioral factors. Positive HPV16 serology was strongly associated with HPV 16 oropharyngeal cancer.
我们推测病毒和宿主因素会影响人乳头瘤病毒阳性口咽癌(HPVOPC)患者对HPV早期抗原的血清学反应。
我们开展了一项多中心研究,以检测HPVOPC患者、其长期性伴侣和健康志愿者体内的HPV16特异性IgG。收集了危险因素调查问卷以及漱口和含漱标本。使用可编程酶联免疫吸附测定法评估诊断时外周血样本中针对HPV16抗原的IgG抗体。采用单变量和多变量线性回归评估HPV16血清学反应的预测因素。
共纳入116例HPVOPC患者、43名伴侣和81名健康志愿者,并采集了基线血清用于分析。病例主要为男性(90%),中位年龄为56岁。与志愿者或伴侣血清相比,HPVOPC患者中检测到E1、E2、E6或E7抗原抗体的情况更为常见(p<0.0001)。90.6%的病例血清中检测到针对至少一种早期蛋白(E1、E2、E4、E5、E6或E7)的HPV16抗体,伴侣中这一比例为0%,健康志愿者中为7.4%。性别、种族、性行为和病毒整合与抗体反应无关。年龄较小和口腔HPV16拷贝数较高与较高的HPV16 E6和NE2抗体水平相关。
在诊断时,HPVOPC患者中普遍检测到HPV16血清反应性,但在伴侣或健康志愿者中未检测到。病例中的血清反应性与病毒载量和分期相关,而与其他人口统计学或行为因素无关。HPV16血清学阳性与HPV 16口咽癌密切相关。